H-102
4-羟基杜洛西汀-β-D-葡萄糖醛酸苷 溶液
100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®
产品名称
4-羟基杜洛西汀-β-D-葡萄糖醛酸苷 溶液, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®
grade
certified reference material
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
100 μg/mL in methanol
technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
General description
4-Hydroxyduloxetine glucuronide is a metabolite of duloxetine. Duloxetine, marketed in the US under the trade name Cymbalta® is a serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder and to alleviate pain associated with diabetic neuropathy, fibromyalgia, and osteoarthritis. This Certified Spiking Solution® is applicable for use in applications such as clinical toxicology, urine drug testing, and forensic analysis by LC-MS/MS or GC/MS.
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Cymbalta is a registered trademark of Eli Lilly and Co.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes
存储类别
3 - Flammable liquids
wgk
WGK 2
flash_point_f
49.5 °F - closed cup
flash_point_c
9.7 °C - closed cup
法规信息
危险化学品
此项目有
M A Smit et al.
Oncogene, 30(35), 3735-3744 (2011-04-12)
Anoikis (detachment-induced apoptosis) prevents the survival of cells at inappropriate sites of the body and can therefore act as a barrier to metastasis. In a function-based genome-wide screen, we have previously identified the neurotrophic tyrosine kinase receptor TrkB as a
Deyin Xing et al.
Cancer research, 69(21), 8231-8235 (2009-10-22)
Uterine leiomyosarcoma (ULMS) is a rare gynecologic malignancy with a low survival rate. Currently, there is no effective treatment for ULMS. Infrequent occurrences of human ULMS hamper the understanding of the initiation and progression of the disease, thereby limiting the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持